Merck & Co. stock: At EUR 128.95, Merck & Co. stock falls 5.14 percent

Published on 10/23/2026 at 15:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Merck's ESMO event is October 26, 2026. Merck & Co. stock costs EUR 128.95 on October 23, 2026, down 5.14 percent versus the Xetra close.

Price move and upcoming dates

Merck & Co. stock fell 5.14 percent versus the Xetra close on October 23, 2026.
Merck will hold its oncology investor event on October 26, 2026.
Merck & Co. stock costs EUR 128.95 at Lang & Schwarz, 5.14 percent below the Xetra close.
Third-quarter results are scheduled for October 29, 2026.

Bunte Pop-Art-Comic-Illustration eines Wissenschaftlers mit Spritze und Ampulle — Pop-Art-Comic mit Laborwissenschaftler und Spritze illustriert Innovationskraft von Merck & Co. Inc., ISIN US58933Y1055, Illustration mit AI erstellt.

Merck & Co. (ISIN US58933Y1055) was trading at EUR 128.95 at Lang & Schwarz on October 23, 2026 at 3:38 p.m. CEST, down 5.14 percent versus the Xetra close of October 22, 2026 at EUR 135.94. The next scheduled company event is the oncology investor meeting at ESMO on October 26, 2026, according to Merck.

ESMO puts the pipeline next

Merck said on October 13, 2026 that the ESMO Congress would feature first-time results from three pivotal Phase 3 trials. The program includes INTerpath-001 in melanoma, TroFuse-005 in endometrial cancer and KEYNOTE-C93 in mismatch repair deficient endometrial cancer. The oncology investor event is set for October 26 at 7:30 p.m. CET in Madrid.

Sales rose in second quarter

Merck reported worldwide sales of USD 16.6 billion for the second quarter of 2026, up from USD 16.3 billion in the first quarter of 2026, according to the company's investor-relations page. The same page identifies the company as listed on the NYSE under ticker MRK and describes continued strength in oncology and animal health.

Goldman Sachs cut its price target from USD 160.00 to USD 155.00 on October 16, 2026, while keeping its Buy rating, according to MarketScreener. At the NYSE, Merck was last quoted at USD 144.51 on October 23, 2026 at 9:52 a.m. ET, putting the new target 7.26 percent above that price.

October 26 comes before results

Merck is due to present its oncology strategy and program at ESMO on October 26, 2026. The company is scheduled to release third-quarter 2026 sales and earnings on October 29, 2026, according to Merck.

Comparison with peers

Merck & Co.: down 5.14 percent, P/E 115.67, market capitalization USD 356.5 billion.
Bristol-Myers Squibb (NYSE, USD): down 0.85 percent, P/E 13.77, market capitalization USD 127.6 billion.
Pfizer (NYSE, USD): down 1.04 percent, P/E 39.74, market capitalization USD 171.6 billion.

Stock trades below the Xetra close

Merck & Co. was trading at EUR 128.95 at Lang & Schwarz on October 23, 2026 at 3:38 p.m. CEST, 5.14 percent below the Xetra close of October 22, 2026 at EUR 135.94. The primary listing is on the NYSE, where the stock was last quoted at USD 144.51 on October 23, 2026 at 9:52 a.m. ET. The further course of trading is shown by the continuously updated real-time quote of Merck & Co. stock.